We first analyzed Swedish cases and controls (N=11,244), and then conducted a meta-analysis with the PGC results for schizophrenia to evaluate our results with respect to the world's literature (N=20,899 after removing 954 subjects from Sw1-2). 17 To maximize comparability, the Swedish samples were run through the same analytical pipeline used for the PGC samples. Association testing was carried out in PLINK using imputed SNP dosages and the principal components described above as covariates. 22 Meta-analysis was conducted using an inverse-weighted fixed effects model. 21 To evaluate the comparability of the Swedish results with those from the PGC schizophrenia study, we used sign tests and risk score profiling based on sets of carefully selected SNPs. 17
